Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells
Archana Bommi‐Reddy, Sungmi Park-Chouinard, David N. Mayhew, et al.
PLoS ONE (2022) Vol. 17, Iss. 3, pp. e0262378-e0262378
Open Access | Times Cited: 10

Showing 10 citing articles:

Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy
Jeffrey D. White, Frederick A. Derheimer, Kristen Jensen-Pergakes, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 3, pp. 243-254
Open Access | Times Cited: 20
EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells
Jasmin Huttunen, Niina Aaltonen, Laura Helminen, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 4
Histone acetylation modulators in breast cancer
Xueying Yuan, Jeffrey M. Rosen
Breast Cancer Research (2025) Vol. 27, Iss. 1
Open Access
Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer
Jin Sun Lee, Susan E. Yost, Sierra Min Li, et al.
Cancers (2022) Vol. 14, Iss. 13, pp. 3159-3159
Open Access | Times Cited: 13
Targeting lysine acetylation readers and writers
Ming‐Ming Zhou, Philip A. Cole
Nature Reviews Drug Discovery (2024)
Closed Access | Times Cited: 2
RNF6 promotes gastric cancer progression by regulating CCNA1/CREBBP transcription
Qiuyu Jiang, Jiyu Miao, Fei Wu, et al.
Cell Cycle (2023) Vol. 22, Iss. 18, pp. 2018-2037
Closed Access | Times Cited: 6
Comparative Analysis of Drug-like EP300/CREBBP Acetyltransferase Inhibitors
McKenna C. Crawford, Deepika R. Tripu, Samuel A. Barritt, et al.
ACS Chemical Biology (2023) Vol. 18, Iss. 10, pp. 2249-2258
Open Access | Times Cited: 5
Genetic dysregulation of EP300 in cancers in light of cancer epigenome control – perspectives of specific targeting of p300 proficient and deficient cancers
Karolina Gronkowska, Agnieszka Robaszkiewicz
Deleted Journal (2024) Vol. 32, Iss. 4, pp. 200871-200871
Closed Access
Comparative analysis of drug-like EP300/CREBBP acetyltransferase inhibitors
McKenna C. Crawford, Deepika R. Tripu, Samuel A. Barritt, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
The Role of Acetyltransferase in Breast Cancer
Zilai Hu, Jia Li, Hu Wang, et al.
(2024)
Closed Access
Page 1

Scroll to top